[18F]Tetrafluoroborate PET/CT for detecting differentiated thyroid cancer: phase-II study protocol

Hannelore I Coerts; Tessa M van Ginhoven; W Edward Visser; Albert D Windhorst; Menno R Vriens; Marc J C van Treijen; Bart de Keizer; Frederik A Verburg

doi:10.1080/14796694.2025.2560294

[18F]Tetrafluoroborate PET/CT for detecting differentiated thyroid cancer: phase-II study protocol

Hannelore I Coerts
, Tessa M van Ginhoven
, W Edward Visser
, Albert D Windhorst
, Menno R Vriens
, Marc J C van Treijen
, Bart de Keizer
, Frederik A Verburg^*

^*Corresponding author for this work

Research output: Contribution to journal › Article › Academic › peer-review

3 Downloads (Pure)

Abstract

AIMS: This study aims to evaluate the diagnostic potential of [ 18F]TFB PET/CT for detecting pre-operative lymph node metastases and predicting [ 131I] therapy response in differentiated thyroid cancer (DTC).

METHODS: This prospective, multicenter phase-2 clinical trial includes adult patients with DTC and pathologically confirmed cervical lymph node metastases scheduled for thyroidectomy and lymph node dissection (Group 1) and patients with recurrent or persistent DTC scheduled for radioiodine therapy (Group 2). [ 18F]TFB PET/CT will be compared to current imaging modalities and post-therapy scintigraphy. Primary outcomes include optimal imaging time points, sensitivity, specificity, SUV max, and TBR max for lymph node metastases and suspected lesions. Secondary outcomes involve [ 18F]TFB kinetics, NIS expression correlation, and safety profiles. In conclusion, [ 18F]TFB PET/CT holds the potential for enhancing pre-operative lymph node metastasis detection and predicting [ 131I] therapy response, potentially improving surgical and therapeutic outcomes for DTC patients.

Original language	English
Pages (from-to)	3167-3174
Number of pages	8
Journal	Future Oncology
Volume	21
Issue number	24
DOIs	https://doi.org/10.1080/14796694.2025.2560294
Publication status	Published - Oct 2025

Keywords

Adult
Clinical Trials, Phase II as Topic
Female
Fluorine Radioisotopes
Humans
Iodine Radioisotopes/therapeutic use
Lymphatic Metastasis/diagnostic imaging
Male
Middle Aged
Multicenter Studies as Topic
Positron Emission Tomography Computed Tomography/methods
Prospective Studies
Radiopharmaceuticals
Thyroid Neoplasms/pathology
Thyroidectomy

Access to Document

10.1080/14796694.2025.2560294Licence: CC BY-NC-ND

18F Tetrafluoroborate PET CT for detecting differentiated thyroid cancer phase-II study protocolFinal published version, 4.06 MBLicence: CC BY-NC-ND

Cite this

@article{9a1cc2b6b5c64c4e989b60108c42c8f6,

title = "[18F]Tetrafluoroborate PET/CT for detecting differentiated thyroid cancer: phase-II study protocol",

abstract = "AIMS: This study aims to evaluate the diagnostic potential of [ 18F]TFB PET/CT for detecting pre-operative lymph node metastases and predicting [ 131I] therapy response in differentiated thyroid cancer (DTC). METHODS: This prospective, multicenter phase-2 clinical trial includes adult patients with DTC and pathologically confirmed cervical lymph node metastases scheduled for thyroidectomy and lymph node dissection (Group 1) and patients with recurrent or persistent DTC scheduled for radioiodine therapy (Group 2). [ 18F]TFB PET/CT will be compared to current imaging modalities and post-therapy scintigraphy. Primary outcomes include optimal imaging time points, sensitivity, specificity, SUV max, and TBR max for lymph node metastases and suspected lesions. Secondary outcomes involve [ 18F]TFB kinetics, NIS expression correlation, and safety profiles. In conclusion, [ 18F]TFB PET/CT holds the potential for enhancing pre-operative lymph node metastasis detection and predicting [ 131I] therapy response, potentially improving surgical and therapeutic outcomes for DTC patients. ",

keywords = "Adult, Clinical Trials, Phase II as Topic, Female, Fluorine Radioisotopes, Humans, Iodine Radioisotopes/therapeutic use, Lymphatic Metastasis/diagnostic imaging, Male, Middle Aged, Multicenter Studies as Topic, Positron Emission Tomography Computed Tomography/methods, Prospective Studies, Radiopharmaceuticals, Thyroid Neoplasms/pathology, Thyroidectomy",

author = "Coerts, \{Hannelore I\} and \{van Ginhoven\}, \{Tessa M\} and Visser, \{W Edward\} and Windhorst, \{Albert D\} and Vriens, \{Menno R\} and \{van Treijen\}, \{Marc J C\} and \{de Keizer\}, Bart and Verburg, \{Frederik A\}",

note = "Publisher Copyright: {\textcopyright} 2025 The Author(s). Published by Informa UK Limited, trading as Taylor \& Francis Group.",

year = "2025",

month = oct,

doi = "10.1080/14796694.2025.2560294",

language = "English",

volume = "21",

pages = "3167--3174",

journal = "Future Oncology",

issn = "1479-6694",

publisher = "Taylor and Francis Ltd.",

number = "24",

}

TY - JOUR

T1 - [18F]Tetrafluoroborate PET/CT for detecting differentiated thyroid cancer

T2 - phase-II study protocol

AU - Coerts, Hannelore I

AU - van Ginhoven, Tessa M

AU - Visser, W Edward

AU - Windhorst, Albert D

AU - Vriens, Menno R

AU - van Treijen, Marc J C

AU - de Keizer, Bart

AU - Verburg, Frederik A

PY - 2025/10

Y1 - 2025/10

N2 - AIMS: This study aims to evaluate the diagnostic potential of [ 18F]TFB PET/CT for detecting pre-operative lymph node metastases and predicting [ 131I] therapy response in differentiated thyroid cancer (DTC). METHODS: This prospective, multicenter phase-2 clinical trial includes adult patients with DTC and pathologically confirmed cervical lymph node metastases scheduled for thyroidectomy and lymph node dissection (Group 1) and patients with recurrent or persistent DTC scheduled for radioiodine therapy (Group 2). [ 18F]TFB PET/CT will be compared to current imaging modalities and post-therapy scintigraphy. Primary outcomes include optimal imaging time points, sensitivity, specificity, SUV max, and TBR max for lymph node metastases and suspected lesions. Secondary outcomes involve [ 18F]TFB kinetics, NIS expression correlation, and safety profiles. In conclusion, [ 18F]TFB PET/CT holds the potential for enhancing pre-operative lymph node metastasis detection and predicting [ 131I] therapy response, potentially improving surgical and therapeutic outcomes for DTC patients.

AB - AIMS: This study aims to evaluate the diagnostic potential of [ 18F]TFB PET/CT for detecting pre-operative lymph node metastases and predicting [ 131I] therapy response in differentiated thyroid cancer (DTC). METHODS: This prospective, multicenter phase-2 clinical trial includes adult patients with DTC and pathologically confirmed cervical lymph node metastases scheduled for thyroidectomy and lymph node dissection (Group 1) and patients with recurrent or persistent DTC scheduled for radioiodine therapy (Group 2). [ 18F]TFB PET/CT will be compared to current imaging modalities and post-therapy scintigraphy. Primary outcomes include optimal imaging time points, sensitivity, specificity, SUV max, and TBR max for lymph node metastases and suspected lesions. Secondary outcomes involve [ 18F]TFB kinetics, NIS expression correlation, and safety profiles. In conclusion, [ 18F]TFB PET/CT holds the potential for enhancing pre-operative lymph node metastasis detection and predicting [ 131I] therapy response, potentially improving surgical and therapeutic outcomes for DTC patients.

KW - Adult

KW - Clinical Trials, Phase II as Topic

KW - Female

KW - Fluorine Radioisotopes

KW - Humans

KW - Iodine Radioisotopes/therapeutic use

KW - Lymphatic Metastasis/diagnostic imaging

KW - Male

KW - Middle Aged

KW - Multicenter Studies as Topic

KW - Positron Emission Tomography Computed Tomography/methods

KW - Prospective Studies

KW - Radiopharmaceuticals

KW - Thyroid Neoplasms/pathology

KW - Thyroidectomy

U2 - 10.1080/14796694.2025.2560294

DO - 10.1080/14796694.2025.2560294

M3 - Article

C2 - 40980865

SN - 1479-6694

VL - 21

SP - 3167

EP - 3174

JO - Future Oncology

JF - Future Oncology

IS - 24

ER -

[18F]Tetrafluoroborate PET/CT for detecting differentiated thyroid cancer: phase-II study protocol

Abstract

Keywords

Access to Document

Fingerprint

Cite this